NCT04541329View on ClinicalTrials.gov

Predicting Inflammatory Skin Disease Response to IL-23 Blockade

PHASE4CompletedINTERVENTIONAL
Enrollment

7

Participants

Timeline

Start Date

September 16, 2020

Primary Completion Date

January 15, 2023

Study Completion Date

January 15, 2023

Conditions
Psoriasis Vulgaris
Interventions
BIOLOGICAL

Tildrakizumab

IL-23 inhibitor

Trial Locations (1)

94158

University of California, San Francisco, San Francisco

All Listed Sponsors
collaborator

Sun Pharmaceutical Industries Limited

INDUSTRY

lead

University of California, San Francisco

OTHER

NCT04541329 - Predicting Inflammatory Skin Disease Response to IL-23 Blockade | Biotech Hunter | Biotech Hunter